Nomura Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,692
Closed -$504K 1753
2025
Q1
$560K Buy
+1,692
New +$556K ﹤0.01% 1449
2024
Q4
Sell
-1,394
Closed -$392K 2311
2024
Q3
$296K Buy
+1,394
New +$357K ﹤0.01% 1346
2023
Q3
Sell
-1,000
Closed -$231K 1531
2023
Q2
$231K Buy
+1,000
New +$271K ﹤0.01% 1156
2020
Q2
Sell
-3,500
Closed -$233K 1212
2020
Q1
$233K Buy
+3,500
New +$292K ﹤0.01% 741
2019
Q3
Sell
-27,500
Closed -$2.91M 1323
2019
Q2
$2.91M Buy
+27,500
New +$2.95M 0.01% 609
2015
Q4
Sell
-4,187
Closed -$254K 1989
2015
Q3
$254K Buy
4,187
+433
+12% +$31.2K ﹤0.01% 1275
2015
Q2
$292K Buy
+3,754
New +$315K ﹤0.01% 1463
2015
Q1
Sell
-3,182
Closed -$300K 2069
2014
Q4
$300K Sell
3,182
-7,819
-71% -$809K ﹤0.01% 1909
2014
Q3
$1.17M Buy
11,001
+1,814
+20% +$252K ﹤0.01% 1382
2014
Q2
$1.31M Buy
9,187
+330
+4% +$48.2K ﹤0.01% 1329
2014
Q1
$1.36M Buy
8,857
+1,846
+26% +$364K ﹤0.01% 1350
2013
Q4
$1.28M Buy
7,011
+4,566
+187% +$836K 0.01% 886
2013
Q3
$538K Buy
2,445
+612
+33% +$130K ﹤0.01% 1362
2013
Q2
$319K Buy
+1,833
New +$478K ﹤0.01% 1564

Other funds holding MDGL

Nomura Holdings's MDGL Position: Q2 2025 in Review

Nomura Holdings sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 1,692 shares — an estimated $504K sold.

Nomura Holdings first reported a position in MDGL in Q2 2013 and held it in 14 quarters. The position peaked at $2.91M in Q2 2019. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Nomura Holdings reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nomura Holdings sold 1,692 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $504K.
  • Nomura Holdings first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Nomura Holdings's Madrigal Pharmaceuticals position peaked at $2.91M in Q2 2019.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Nomura Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.